Cliff Asness's CGEM Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 581,338 shares of Cullinan Therapeutics, Inc. (CGEM) worth $10.59 M, representing 0.00% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in CGEM, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 220,464 shares. Largest reduction occurred in Q3 2023, reducing 50,048 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Cullinan Therapeutics (CGEM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cullinan Therapeutics (CGEM) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +220,464 | Add 61.09% | 581,338 | $18.21 |
| Q1 2026 | +79,391 | Add 28.20% | 360,874 | $14.21 |
| Q4 2025 | +83,563 | Add 42.22% | 281,483 | $10.35 |
| Q3 2025 | +177,000 | Add 846.08% | 197,920 | $5.93 |
| Q2 2025 | +20,920 | New Buy | 20,920 | $7.53 |
| Q4 2023 | -21,774 | Sold Out | 0 | $0.00 |
| Q3 2023 | -50,048 | Reduce 69.68% | 21,774 | $9.05 |
| Q2 2023 | -16,470 | Reduce 18.65% | 71,822 | $10.76 |
| Q1 2023 | -23,068 | Reduce 20.71% | 88,292 | $10.23 |
| Q4 2022 | +2,958 | Add 2.73% | 111,360 | $10.55 |
| Q3 2022 | +87,493 | Add 418.45% | 108,402 | $12.82 |
| Q2 2022 | +20,909 | New Buy | 20,909 | $12.82 |
Cliff Asness's Cullinan Therapeutics Investment FAQs
Cliff Asness first purchased Cullinan Therapeutics, Inc. (CGEM) in Q2 2022, acquiring 20,909 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Cullinan Therapeutics, Inc. (CGEM) for 12 quarters since Q2 2022.
Cliff Asness's largest addition to Cullinan Therapeutics, Inc. (CGEM) was in Q2 2026, adding 581,338 shares worth $10.59 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 581,338 shares of Cullinan Therapeutics, Inc. (CGEM), valued at approximately $10.59 M.
As of the Q2 2026 filing, Cullinan Therapeutics, Inc. (CGEM) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Cullinan Therapeutics, Inc. (CGEM) was 581,338 shares, as reported at the end of Q2 2026.